Cancer News and Research

Latest Cancer News and Research

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

10 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Health care reform should benefit shift workers: Circadian Age

Circadian Age, Inc. – ‘Working Nights’ – a company dedicated to helping shift workers and their families adjust to their unique lifestyles, is concerned with making sure that any health care reform will benefit the 25 million Americans working shifts. These workers represent 10% of the insured population, but incur 17% of the health care costs.

10 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

SAVI reaches a major milestone in breast brachytherapy

This month marks three years since physicians began offering SAVI™ radiation treatment as part of breast conservation therapy for early-stage breast cancer – a major milestone in breast brachytherapy.

10 Nov 2009

AMP's four-day event on the latest advances in clinical molecular diagnostics

The Association for Molecular Pathology (AMP) invites the media to follow its upcoming 2009 Annual Meeting and Exhibits and learn about the latest advances in clinical molecular diagnostics.

10 Nov 2009

Lesser rates of kidney/pancreas transplants for African Americans: Is physician bias the reason?

Physician bias might be the reason why African Americans are not receiving kidney/pancreas transplants at the same rate as similar patients in other racial groups. Dr. Keith Melancon, director of kidney and pancreas transplantation at Georgetown University Hospital and associate professor of surgery at Georgetown University Medical Center, and colleagues explore this phenomenon in the November issue of the American Journal of Transplantation.

10 Nov 2009

Study suggests a new improved treatment option for children with Hurler's syndrome

Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme - preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

10 Nov 2009

NATC sponsored national quit smoking program to launch second phase of campaign

With the latest research estimating that nearly six million people worldwide will lose their lives to tobacco next year, an innovative approach is critical to helping the 43 million Americans who smoke to finally quit. This month, which is observed as Lung Cancer Awareness Month, the national quit smoking program, EX(R) will debut the second phase of advertising and promotions designed to help smokers "re-learn" life without cigarettes.

10 Nov 2009

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.

10 Nov 2009

Disparities in emergency room waiting times for chest pain patients

Emory University Rollins School of Public Health researchers will present Nov. 10 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that examined compliance with national recommendations that a physician screen chest pain patients within 10 minutes of their arrival to the Emergency Department (ED).

10 Nov 2009

Activating TAp63 protein, a viable anti-cancer strategy

Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated.

10 Nov 2009

Scientists find way to splice cell networks down to their genesis

On Noah's Ark animals came in twos: male and female. In human bodies trillions of cells are coupled, too, and so are the molecules from which they are composed. Yet these don't come in twos, they are regrouped into indistinguishable clusters. Because these complex cell networks are the backbone of life - and illness - scientists have long searched for ways to splice cell clusters down to their original pairs.

10 Nov 2009

Environmental factors, obesity and diabetes: Long-term study launched

Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.

10 Nov 2009

Children with ASD have problem with handwriting: Study

Handwriting skills are crucial for success in school, communication, and building children's self-esteem. The first study to examine handwriting quality in children with autism spectrum disorders (ASD) has uncovered a relationship between fine motor control and poor quality of handwriting in children with ASD, according to research published in the November 10, 2009, issue of Neurology-, the medical journal of the American Academy of Neurology.

10 Nov 2009

New imagining technique may yield better antiviral and anti-cancer drugs

A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist.

10 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Aduro BioTech raises funds through its Series A-1 financing

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

BioVex completes $70M financing to complete OncoVEX Phase III study

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Health care reform should benefit shift workers: Circadian Age

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

SAVI reaches a major milestone in breast brachytherapy

AMP's four-day event on the latest advances in clinical molecular diagnostics

Lesser rates of kidney/pancreas transplants for African Americans: Is physician bias the reason?

Study suggests a new improved treatment option for children with Hurler's syndrome

NATC sponsored national quit smoking program to launch second phase of campaign

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

Disparities in emergency room waiting times for chest pain patients

Activating TAp63 protein, a viable anti-cancer strategy

Scientists find way to splice cell networks down to their genesis

Environmental factors, obesity and diabetes: Long-term study launched

Children with ASD have problem with handwriting: Study

New imagining technique may yield better antiviral and anti-cancer drugs

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in